The CGPA and Biosimilars Canada have acknowledged the risk of local shortages amid the coronavirus crisis, after Health Canada advised Canadians that buying more medicine than usual could lead to local supply disruptions.
Demand-related shortages for specific medicines in Canada due to the coronavirus pandemic have been acknowledged by the Canadian Generic Pharmaceutical Association and Biosimilars Canada, which said they were working with other key industry players to mitigate supply chain disruptions.
Jim Keon, president of the CGPA and Biosimilars Canada, said the associations were “working closely with Health Canada, member companies...
Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.
The Federal Circuit has temporarily blocked MSN from launching a generic version of Entresto, granting Novartis short-term relief while it reviews the company’s emergency Rule 8 motion for a longer injunction.
As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.
Wockhardt is exiting the US generics market through voluntary liquidation of its loss-making US subsidiaries to double down on innovation and focus on antibiotics and biosimilar insulins.
